부산대학교 도서관

Anti-VEGF therapies have proven to be overall safe; however, inflammatory events, which are generally manageable, are a common reoccurring theme of anti-VEGF treatments, suggesting a possible link between VEGF inhibition and inflammation.[4] There also is an increasing body of literature indicating that VEGF plays an important neuroprotective role in the retina.[[5]] Consequently, alternative avenues are being pursued to treat neovascular pathologies without affecting VEGF function.[16] In a companion article to this editorial, we show that inhibition of VEGF by rAAV2.7m8-mediated gene transfer of conbercept, a recently developed anti-VEGF protein, can cause a vascular sheathing pathology, which is reminiscent of vasculitis in humans at a high dose. A recent announcement from Adverum Biotechnology reports that a clinical trial (NCT04418427) patient lost sight in the treated eye after recombinant adeno-associated virus (rAAV)-mediated gene transfer of the anti-vascular endothelial growth factor (VEGF) drug aflibercept (Eylea). Compounded with a disease-associated inflammation that is common in patients with edemas,[19],[20] inhibition of VEGF could result in more severe inflammatory events. Thus, the severe adverse event in the patient treated with AAV2.7m8 I Aflibercept i could have been caused by a combination of excessive inflammation due to the disease condition and inhibition of VEGF function, which over time would have further exacerbated the disease-associated inflammation. [Extracted from the article]